Diagnostic vs. Screening Mammograms: What’s the Difference?
November 28, 2016
Smoking declines dramatically but linked to 40 percent of cancer cases
November 29, 2016
Show all

Better Stem Cell Approach for MS and Other Ills

Efforts to make stem cell transplant more widely available.

Magenta Therapeutics has completed its first round of financing, raising $48.5 million to develop ways of bringing stem cell transplants to more patients with autoimmune diseases, such as multiple sclerosis (MS), among other illnesses.

The new company aims to develop the first complete platform that can overcome the challenges in stem cell transplants, taking a patient-focused approach, it announced in a press release.

By improving the preparation of patients using antibodies, as well as making the gathering and expansion of stem cells more efficient, the company hopes to change the entire approach to transplant use, so that the therapy is more widely applicable. In addition to autoimmune diseases, the company is also focusing on treating people with genetic blood disorders and cancer.

“Technical and scientific hurdles have relegated stem cell transplantation to a last resort for deadly diseases today, but new science is ready to be advanced to the clinic that could fundamentally open up this powerful medicine to patients suffering from earlier stage cancers, blood disorders and a large set of aggressive autoimmune diseases, including multiple sclerosis and scleroderma,” Jason Gardner, chief executive officer, president, and co-founder of Magenta Therapeutics, said in the release.

Read Full Article: Better Stem Cell Approach for MS and Other Ills Goal of Magenta Therapeutics

Read Full Article: Better Stem Cell Approach for MS and Other Ills Goal of Magenta Therapeutics

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.